Review Article
Metastatic Pancreatic Cancer: Are We Making Progress in Treatment?
Table 1
Major phase III GEM-based combination chemotherapy.
| | Regime | No. pts | ORR (%) | PFS/TTP (mo) | OS (mo) | Reference |
| | GEM + cisplatin | 195 | 10.2 | 5.3 | 7.5 |
Heinemann et al. [4] | | GEM | | 8.2 | 3.1 | 6.0 | | GEM + oxaliplatin | 832 | () | 2.7 | 5.7 | Poplin et al. [5] | | GEM | | | 2.6 | 4.9 | | GEM + 5FU | 322 | 6.9 | 3.4* | 6.7 | Berlin et al. [7] | | GEM | | 5.6 | 2.2 | 5.4 |
*
P = 0.022 | | GEM + capecitabine | 533 | 19.2 | 5.3 | 7.1 | Cunningham et al. [9] | | GEM | | 12.4 | 3.8 | 6.2 | | GEM + capecitabine
GEM | 319 | QoL same | n/a | n/a | Bernhard et al. [10] | | GEM + capecitabine | 319 | 10.0 | 4.3 | 8.4 (10.1*) | Herrmann et al. [11] | | GEM | | 7.8 | 3.9 | 7.2 (7.4) | (*KPS 90–100; ) |
|
|
Abbreviation: ORR: overall response rate; PFS: progression free survival; TTP: time to progression; OS: overall survival; QoL: quality of life.
|
